SCP
FATE icon

Syntal Capital Partners’s Fate Therapeutics FATE Stock Holding History

Syntal Capital Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,697
Closed -$2.34M – 131
2020
Q4 		$2.34M Buy
+25,697
New +$1.6M 0.29% 21

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Syntal Capital Partners's FATE Position: Q1 2021 in Review

Syntal Capital Partners sold out of Fate Therapeutics (FATE) in Q1 2021, closing a stake of 25,697 shares — an estimated $2.34M sold.

Syntal Capital Partners first reported a position in FATE in Q4 2020 and held it in 1 quarter. The position peaked at $2.34M in Q4 2020. 260 funds tracked by Wall St. Rank hold FATE as of Q1 2021.

  • Syntal Capital Partners reported no remaining Fate Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Syntal Capital Partners sold 25,697 Fate Therapeutics shares in Q1 2021, an estimated $2.34M.
  • Syntal Capital Partners first reported a position in Fate Therapeutics in Q4 2020 and held it in 1 quarter.
  • Syntal Capital Partners's Fate Therapeutics position peaked at $2.34M in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2021.

Based on Syntal Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.